World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
33398
World Ranking
11684
National Ranking
5990

Overview

Harold E. Bays is affiliated with the Louisville Metabolic and Atherosclerosis Research Center in the United States. Their research contributions span multiple areas within medicine, with a focus on surgery, endocrinology, diabetes and metabolism, pharmacology, physiology, and cardiology and cardiovascular medicine.

Their work primarily addresses topics including pharmacology and obesity treatment, diet and metabolism studies, lipoproteins and cardiovascular health, diabetes treatment and management, obesity and health practices, diabetes, cardiovascular risks and lipoproteins, and bariatric surgery and outcomes.

Harold E. Bays has contributed to several peer-reviewed journals, frequently publishing in venues such as Obesity Pillars with 45 publications, Journal of Clinical Lipidology with 10, American Journal of Preventive Cardiology with 6, Journal of the American College of Cardiology with 6, and Obesity with 4.

Their recent significant papers include:

  • Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity, 2021, JAMA
  • Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients, 2023, New England Journal of Medicine
  • Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity, 2023, JAMA
  • Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation, 2022, European Journal of Preventive Cardiology
  • Ten things to know about ten cardiovascular disease risk factors, 2021, American Journal of Preventive Cardiology

Frequent co-authors collaborating with Harold E. Bays include:

  • Kausik K. Ray
  • Angela Fitch
  • Alberico L. Catapano
  • Christie M. Ballantyne
  • Maciej Banach

Overall, Harold E. Bays maintains a comprehensive research portfolio centered on the intersection of metabolic disorders, cardiovascular health, and therapeutic interventions related to obesity, diabetes, and lipid management. Their publications reflect multidisciplinary approaches that combine clinical investigation with pharmacological and physiological studies.

Best Publications

  • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)

    Peter H Jones;Michael H Davidson;Evan A Stein;Harold E Bays

  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Adrian F Hernandez;Jennifer B Green;Salim Janmohamed;Ralph B D'Agostino

  • Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

    Steven R. Smith;Neil J. Weissman;Christen M. Anderson;Matilde Sanchez

  • National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

    Terry A. Jacobson;Matthew K. Ito;Kevin C. Maki;Carl E. Orringer

  • Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

    Claude Gagné;Harold E Bays;Stuart R Weiss;Pedro Mata

  • National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

    Terry A. Jacobson;Kevin C. Maki;Carl E. Orringer;Peter H. Jones

  • Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity.

    Harold E Bays;J Michael González-Campoy;George A Bray;Abbas E Kitabchi

  • Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.

    Kausik K. Ray;Harold E. Bays;Alberico L. Catapano;Narendra D. Lalwani

  • National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

    Terry A. Jacobson;Matthew K. Ito;Kevin C. Maki;Carl E. Orringer

  • The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys

    H. E. Bays;R. H. Chapman;S. Grandy

  • Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study

    Michael H Davidson;Evan A Stein;Harold E Bays;Kevin C Maki

  • Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association

    Harold E. Bays;Peter P. Toth;Penny M. Kris-Etherton;Nicola Abate

  • Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

    R.H. Knopp;H. Gitter;T. Truitt;H. Bays

  • Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

    Michael J. Koren;Pernille Lundqvist;Michael Bolognese;Joel M. Neutel

  • Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)

    Harold E. Bays;Christie M. Ballantyne;John J. Kastelein;Jonathan L. Isaacsohn

  • Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.

    Priscilla Hollander;Alok K. Gupta;Raymond Plodkowski;Frank Greenway

  • Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)

    Christie M. Ballantyne;Harold E. Bays;John J. Kastelein;Evan Stein

  • Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

    Harold E Bays;Paul B Moore;Margaret A Drehobl;Sidney Rosenblatt

  • Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

    Frederick J. Raal;Robert P. Giugliano;Marc S. Sabatine;Michael J. Koren

  • Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications

    Harold E Bays;Ann P Tighe;Richard Sadovsky;Michael H Davidson

Frequent Co-Authors

Christie M. Ballantyne
Christie M. Ballantyne Baylor College of Medicine
Evan A. Stein
Evan A. Stein Medpace (United States)
Michael H. Davidson
Michael H. Davidson University of Chicago
Peter Jones
Peter Jones University of Cambridge
Kausik K. Ray
Kausik K. Ray Imperial College London
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Alberico L. Catapano
Alberico L. Catapano University of Milan
Lawrence A. Leiter
Lawrence A. Leiter University of Toronto
Maciej Banach
Maciej Banach John Paul II Catholic University of Lublin
Terry A. Jacobson
Terry A. Jacobson Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers beyond a traditional MD program, there are numerous flexible options available online. Those looking for administrative or support roles can explore the best online medical billing and coding schools, which offer accredited programs with financial aid opportunities.

If nursing is your passion but you’re concerned about tough admissions processes, consider the nursing school no entrance exam options. These programs remove barriers like the TEAS or HESI exams, making it easier to start your nursing education.

Aspiring healthcare leaders should look into online health administration programs for an accelerated path to management positions in hospitals and clinics. For practicing nurses, the asn to np bridge programs offer a streamlined way to advance from an associate’s degree to becoming a nurse practitioner.

Whatever your background, these diverse online pathways help you enter or advance in the healthcare field while balancing work, life, and study.

Best Scientists Citing Harold E. Bays

Trending Scientists